Stryker (SYK) has drawn fresh investor attention after reporting second quarter 2026 results, with sales of US$6.6b and net income of US$1.3b, alongside higher earnings per share from continuing operations.

The sharp 1 day share price decline of 6.42% to US$325.70 after Stryker’s earnings reflects investor focus on softer organic sales and ongoing supply disruptions, even though the 3 month share price return of 10.51% and 5 year total shareholder return of 30.66% still point to longer term momentum.

If Stryker’s latest results have you rethinking where growth in medical technology could come from next, it may be worth scanning for other opportunities in healthcare focused AI using the 41 healthcare AI stocks

Stryker’s strong quarterly figures sit next to a sharp pullback in the share price, which leaves a clear tension. Has most of the upside already played out, or does the recent drop still leave meaningful value on the table?

Most Popular Narrative: 15.8% Undervalued

Stryker’s most followed valuation story currently points to a fair value of $386.80, which sits well above the last close at $325.70 and frames the recent pullback in a different light.

Robust innovation pipeline, particularly in robotic-assisted surgery (Mako platform) and next-generation devices, is driving greater market share, higher average selling prices, and service revenues, which is expected to accelerate both revenue and margin expansion over time.

Want to see what sits behind that confidence in Stryker’s future cash flows? The narrative leans on steady revenue compounding, rising margins and a richer earnings base ahead. The key is how these assumptions stack up against today’s price.

Result: Fair Value of $386.80 (UNDERVALUED)

However, Stryker’s story could be tested if European regulatory delays persist, or if ongoing supply chain issues and tariffs squeeze margins harder than analysts currently model.

Another View: Stryker Looks Expensive On P/E

The SWS DCF work suggests Stryker is trading below estimated future cash flow value, yet the P/E picture is tougher. At 33.5x earnings, the stock sits above the US Medical Equipment industry on 29x and the peer average of 28.8x, and is only slightly under the 34.5x fair ratio. That points to less room for error if earnings disappoint.

Next Steps

Conflicted about whether recent Stryker moves signal more upside or a ceiling forming? Act while the data is fresh, review both sides of the story, then weigh the 3 key rewards and 2 important warning signs

Looking for more Stryker sized investment ideas?

Do not stop your research with Stryker. Use the Simply Wall St screener to uncover fresh stock ideas that match the kind of portfolio you want to build.

• Target potential upside in quality opportunities that trade below their estimated worth by scanning the 55 high quality undervalued stocks.
• Strengthen your income stream with companies that aim to pay sizeable regular cash returns using the 9 dividend fortresses.
• Prioritise resilience by focusing on companies that carry lower flagged risk using the 81 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.